Cava Group Option Alert: Jun 27 $75 Puts at the Bid: 6250 vs 15 OI

Cava Group Option Alert: Jun 27 $75 Puts at the Bid: 6250 @ $0.86 vs 15 OI; Ref=$90.6337

Cava Group Option Alert: Jul 18 $75 Puts Sweep (3) near the Bid: 5027 vs 365 OI

Cava Group Option Alert: Jul 18 $75 Puts Sweep (3) near the Bid: 5027 @ $1.26 vs 365 OI; Ref=$95.31

Cava Group (NYSE:CAVA) Azioni

CAVA GROUP INC

Cava Group

Cava Group Inc owns and operates a chain of restaurants. It is the category-defining Mediterranean fast-casual restaurant brand, bringing together healthful food and bold, satisfying flavors at scale. The company's dips, spreads, and dressings are centrally produced and sold in grocery stores. The company's operations are conducted as two reportable segments: CAVA and Zoes Kitchen. The company generates all of its revenue from the CAVA segment.

Cava Group Inc

Jefferies analyst David Chiaverini initiates coverage on Webster Financial (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WBS#NYSE">WBS</a>) with a Buy rating and announces Price Target of $65.

News

Price Target

Initiation

Analyst Ratings

Jefferies Initiates Coverage On Webster Financial with Buy Rating, Announces Price Target of $65

Silexion Therapeutics Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLXN#NASDAQ">SLXN</a>) ("Silexion" or the "Company"), a clinical-stage biotech company developing RNA interference (RNAi) therapies for KRAS-driven cancers, today announced the completion of a comprehensive preclinical study assessing SIL204's therapeutic potential across multiple cancer types beyond pancreatic cancer. The Company is currently finalizing its analysis of the data and expects to announce comprehensive results within the next few days.
The now-completed studies evaluated SIL204, the Company's next-generation RNAi therapeutic candidate, in multiple cancer cell lines harboring KRAS mutations: GP2D (colorectal cancer), A427 (lung cancer), and Panc-1 (pancreatic cancer). These cancer types were strategically selected based on their high prevalence of KRAS mutations and significant unmet medical needs.
KRAS mutations are among the most common oncogenic drivers in human cancers, occurring in roughly 90% of pancreatic cancers, about 45% of colorectal cancers, and around 35% of non-squamous non-small-cell lung cancers. Together, these three indications underpin global treatment markets already worth well over US $30 billion a year1, yet most KRAS variants remain difficult to drug with small-molecule or antibody approaches—underscoring the potential significance of Silexion's RNAi-based strategy.

SLXN

Silexion Therapeutics Completes Comprehensive Preclinical Study Assessing SIL204's Therapeutic Potential Across Multiple Cancer Types Beyond Pancreatic Cancer

WIIM

CIFR

Cipher Mining shares are trading lower. The company provided details of the pricing of its senior note offering.

JMP Securities analyst Silvan Tuerkcan reiterates CRISPR Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRSP#NASDAQ">CRSP</a>) with a Market Outperform and maintains $86 price target.

Reiteration

CRSP

JMP Securities Reiterates Market Outperform on CRISPR Therapeutics, Maintains $86 Price Target

Williams-Sonoma, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WSM#NYSE">WSM</a>) will release earnings results for the first quarter, before the <a href="https://www.benzinga.com/quote/WSM/earnings">opening bell on Thursday, May 22.</a>
Analysts expect the San Francisco, California-based company to report quarterly earnings at $1.76 per share, up from $1.74 per share in the year-ago period. Williams-Sonoma projects to report quarterly revenue at $1.67 billion, compared to $1.66 billion a year earlier, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
On Monday, Barclays analyst Seth Sigman upgraded the stock from Underweight to Equal-Weight and raised the price target from $131 to $166.
With the recent buzz around Williams-Sonoma, some investors may be eyeing potential gains from the company's dividends too. As of now, Williams-Sonoma offers an annual dividend yield of 1.53%. That&#8217;s a quarterly dividend amount of 66 cents per share ($2.64 a year).  
So, how can investors exploit its dividend yield to pocket a regular $500 monthly?
To earn $500 per month or $6,000 annually from dividends alone, you would need an investment of approximately $392,138 or around 2,273 shares. For a more modest $100 per month or $1,200 per year, you would need $78,497 or around 455 shares.
To calculate: Divide the desired annual income ($6,000 or $1,200) by the dividend ($2.64 in this case). So, $6,000 / $2.64 = 2,273 ($500 per month), and $1,200 / $2.64 = 455 shares ($100 per month).
Note that dividend yield can change on a rolling basis, as the dividend payment and the stock price both fluctuate over time.
How that works: The dividend yield is computed by dividing the annual dividend payment by the stock&#8217;s current price.
For example, if a stock pays an annual dividend of $2 and is currently priced at $50, the dividend yield would be 4% ($2/$50). However, if the stock price increases to $60, the dividend yield drops to 3.33% ($2/$60). Conversely, if the stock price falls to $40, the dividend yield rises to 5% ($2/$40).
Similarly, changes in the dividend payment can impact the yield. If a company increases its dividend, the yield will also increase, provided the stock price stays the same. Conversely, if the dividend payment decreases, so will the yield.
WSM Price Action: Shares of Williams-Sonoma fell 1% to close at $172.52 on Tuesday.
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="How to Find Dividend Stocks: Scan, Analyze, and Capture with Benzinga Pro" width="500" height="281" src="https://www.youtube.com/embed/pVF0O2lsEH4?start=1&#038;feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
Read More: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/short-ideas/25/05/45517463/top-2-risk-off-stocks-that-are-ticking-portfolio-bombs">Top 2 Risk Off Stocks That Are Ticking Portfolio Bombs</a></li>
</ul>
Image: Shutterstock

Earnings

Long Ideas

Markets

Trading Ideas

How To Earn $500 A Month From Williams-Sonoma Stock Ahead Of Q1 Earnings

Medtronic plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MDT#NYSE">MDT</a>) reported fourth-quarter 2025 sales of $8.93 billion, beating the <a href="https://www.benzinga.com/pressreleases/25/05/n45538067/medtronic-reports-strong-finish-to-its-fiscal-year-with-its-fourth-quarter-financial-results-annou" target="_blank" rel="noreferrer noopener">consensus of $8.82 billion</a>.
The medical device maker reported:
<ul class="wp-block-list">
<li>Adjusted EPS of $1.62, beating the consensus of $1.58.</li>
<li>A year-over-year revenue increase of 3.9% <a href="https://www.benzinga.com/earnings" target="_blank" rel="noreferrer noopener">and 5.4% Y/Y organically</a>.</li>
<li>Cardiovascular segment revenue reaching $3.34 billion, up 6.6% year over year as reported, and increased 7.8% Y/Y organically.</li>
<li>An increase in low-double-digit in CRHF, high-single-digit in SH&amp;A, and low-single-digit in CPV (all on an organic basis).</li>
<li>Neuroscience revenues of $2.62 billion rose 2.9% Y/Y as reported. They rose 3.7% Y/Y organically, aided by an increase in low-double-digit in Neuromodulation and mid-single-digit in CST, all on an organic basis.</li>
<li>Medical Surgical&nbsp;revenue of&nbsp;$2.21 billion increased by&nbsp;0.6% Y/Y&nbsp;as reported and by&nbsp;2.0%&nbsp;Y/Y organically, with a low-single-digit organic growth in both SE and ACM segments.</li>
<li>Diabetes revenue of&nbsp;$728 million increased by&nbsp;10.4% Y/Y, as reported, and by&nbsp;12.0%&nbsp;Y/Y organically.</li>
</ul>
Dividend Increase: Effective May 20, the company&#8217;s board approved an increase in cash dividend per share by 1.4% to 71 cents for the first quarter of fiscal year 2026
The dividend is payable on&nbsp;July 11, 2025, to shareholders of record as of&nbsp;June 27, 2025.
Guidance:&nbsp;Medtronic expects its fiscal year 2026 organic <a target="_blank" href="https://www.benzinga.com/calendars/guidance" rel="noreferrer noopener">revenue&nbsp;growth&nbsp;guidance&nbsp;of&nbsp;5%</a>.
If recent foreign currency exchange rates hold, FY26 revenue growth would be around&nbsp;&nbsp;4.8% to 5.1% on a reported basis.
Medtronic expects 2025 adjusted EPS of&nbsp;$5.50-$5.60&nbsp;versus consensus of&nbsp;$5.83.
Diabetes Business Separation: Medtronic disclosed its intention to separate its Diabetes <a target="_blank" href="https://www.benzinga.com/pressreleases/25/05/n45538032/medtronic-announces-intent-to-separate-diabetes-business" rel="noreferrer noopener">business into a new standalone company</a>.
This move aims to create a more focused entity with a streamlined portfolio concentrated on high-margin growth markets.
The separation, expected within 18 months, will occur through capital markets transactions, with an initial public offering (IPO) followed by a split-off as the preferred method.
Upon separation, Medtronic anticipates an immediate improvement of approximately 50 basis points in adjusted gross margin, 100 basis points in adjusted operating margins, and an immediate accretion to adjusted EPS.
The separation is also expected to allow Medtronic to retire outstanding shares without impacting cash, leading to further EPS accretion and a reduced dividend liability.
Investors can gain exposure to the stock via Madison ETFs Trust Madison Covered Call ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVRD#NYSE">CVRD</a>) and Absolute Select Value ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABEQ#NYSE">ABEQ</a>).
Price Action:&nbsp;MDT stock is down 0.14% at $86.25 premarket at the last check on Wednesday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/25/03/44451449/china-courts-apple-pfizer-eli-lilly-amid-us-pressure-vice-premier-says-beijing-will-continue-to-improve-the-business-environment" target="_blank" rel="noreferrer noopener">China Courts Apple, Pfizer, Eli Lilly Amid US Pressure, Vice Premier Says Beijing &#8216;Will Continue To Improve The Business Environment&#8217;</a></li>
</ul>
Image: Shutterstock

Equities

Large Cap

Guidance

Dividends

ABEQ

CVRD

Medtronic Beats Q4 Forecasts, Hikes Dividend, Plans Diabetes Spinoff

TJX Companies Inc&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TJX#NYSE">TJX</a>) shares&nbsp;are trading lower premarket on Wednesday&nbsp;after the&nbsp;<a target="_blank" href="https://www.benzinga.com/pressreleases/25/05/b45538836/the-tjx-companies-inc-reports-q1-fy26-results-comp-sales-growth-of-3-pretax-profit-margin-of-10-3-" rel="noreferrer noopener">first-quarter&nbsp;FY26 earnings result</a>.
Sales rose 5% year-over-year (Y/Y)&nbsp;to&nbsp;$13.1 billion, beating the analyst consensus estimate of&nbsp;$13.0 billion.
Overall&nbsp;comp store sales increased&nbsp;3% (Y/Y), at the high end of the company's plan, and were driven by an increase in customer transactions.
Also Read: <a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/05/45524193/tjx-companies-q1-preview-report-could-reflect-durable-earnings-growth" target="_blank" rel="noreferrer noopener">TJX Companies Q1 Preview: Report Could Reflect Durable Earnings Growth</a>
Gross&nbsp;profit margin was&nbsp;29.5%, a 0.5&nbsp;percentage point decrease versus the prior year, due to negative mark-to-market adjustments on inventory hedges.
Ernie Herrman, president and CEO said, &#8221;All divisions, both in the U.S. and internationally, drove increases in comp sales and customer transactions, which underscores the strength of our value proposition.&#8221;
Adjusted EPS of&nbsp;92 cents beat the <a target="_blank" href="https://www.benzinga.com/earnings" rel="noreferrer noopener">consensus&nbsp;estimate of&nbsp;90 cents</a>.
The&nbsp;company held&nbsp;$4.3 billion&nbsp;in cash and equivalents&nbsp;as of May 3 and generated&nbsp;$394&nbsp;billion&nbsp;of operating cash flow in the quarter.
As of May 3, total inventories stood at $7.1 billion, compared to&nbsp;$6.2&nbsp;billion&nbsp;last year.
During the first quarter, the company returned a total of $1.0 billion to shareholders, including the repurchase of shares worth $613 million.
The company continues to expect share repurchases of approximately $2.0 billion to $2.5 billion in fiscal 2026.
Outlook: TJX&nbsp;reaffirmed guidance for FY26 comparable sales growth of&nbsp;2%&nbsp;–&nbsp;3% and EPS of&nbsp;$4.34-$4.43&nbsp;<a href="https://www.benzinga.com//node/43976995" target="_blank" rel="noreferrer noopener">against a&nbsp;$4.49&nbsp;estimate</a>.
The company sees&nbsp;second quarter comparable sales growth of&nbsp;2%&nbsp;–&nbsp;3%&nbsp;and&nbsp;EPS of&nbsp;$0.97-$1.00&nbsp;<a target="_blank" href="https://www.benzinga.com/calendars/guidance" rel="noreferrer noopener">with an estimate of&nbsp;$1.03</a>.
TJX&#8217;s second-quarter and FY26 guidance assumes current U.S. import tariffs from China and other nations, as of Wednesday, will persist.
Furthermore, for the full-year FY26, the company expects to fully offset the significant and ongoing tariff-related financial pressures.
Investors can gain exposure to the stock via&nbsp;VanEck Retail ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RTH#NASDAQ">RTH</a>) and iShares U.S. Consumer Focused ETF (BATS:<a class="ticker" href="https://www.benzinga.com/stock/IEDI#BATS">IEDI</a>).
Price Action:&nbsp;TJX shares are down 1.88% at $132.39 premarket at the last check on Wednesday.
Read Next:&nbsp;
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/general/market-summary/25/05/45537307/us-stocks-likely-to-open-lower-expert-says-tariffs-remain-a-headwind-but-tax-cut-and-easing-of-tensions-in-middle-east-could-propel-equities-closer-to-all-time-highs" target="_blank" rel="noreferrer noopener">US Stocks Likely To Open Lower, Expert Says &#8216;Tariffs Remain A Headwind,&#8217; But &#8216;Tax Cut&#8217; And &#8216;Easing Of Tensions&#8217; In Middle East &#8216;Could Propel Equities Closer To All-Time Highs&#8217;</a></li>
</ul>
Photo: Shutterstock

Movers

IEDI

Merrill Lynch Retail HOLDRS Trust due 12/31/41

TJX Boosts Q1 Sales With More Shoppers, Says Tariffs Won't Hurt 2026 Outlook

Target Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TGT#NYSE">TGT</a>) shares are trading lower on Wednesday after the company <a href="https://www.benzinga.com/pressreleases/25/05/n45537768/target-corporation-reports-first-quarter-earnings" target="_blank" rel="noreferrer noopener">reported first-quarter results.</a>
Target registered adjusted earnings per share of $1.30, missing analysts&#8217; consensus estimate of $1.64. Quarterly sales of $23.85 billion (down 2.8% year over year) missed the Street view of $24.32 billion.
&#8220;While our sales fell short of our expectations, we saw several bright spots in the quarter, including healthy digital growth, led by a 36 percent increase in same-day delivery through Target Circle 360, and our strongest designer collaboration in more than a decade, kate spade for Target,&#8221; said&nbsp;Brian Cornell, chair and chief executive officer of Target Corporation.&nbsp;
Also Read: <a target="_blank" href="https://www.benzinga.com/25/05/45535402/target-lowes-and-3-stocks-to-watch-heading-into-wednesday" rel="noreferrer noopener">Target, Lowe&#8217;s And 3 Stocks To Watch Heading Into Wednesday</a>
Comparable sales decreased 3.8% in the first quarter, reflecting a comparable store sales decline of 5.7% and comparable digital sales growth of 4.7%.
The quarterly gross margin rate was 28.2%, lower than 28.8% in the year-ago period, due to the net impact of merchandising activities, including higher markdown rates, digital fulfillment and supply chain costs.
Target&#8217;s operating income gained 13.6% year over year to $1.472 billion.
Operating margin&nbsp;was 6.2 percent in 2025, compared with 5.3 percent in 2024.&nbsp; Excluding&nbsp;the litigation settlement gains, the operating income margin rate was 3.7 percent in the quarter under review.&nbsp;&nbsp;
The company said it has established an acceleration office led by&nbsp;Michael Fiddelke to enable faster decisions and execution of its core strategic initiatives in support of a return to growth.
As of the end of the quarter, Target had approximately&nbsp;$8.4 billion&nbsp;of remaining capacity under the repurchase program approved by the company&#8217;s board of directors in&nbsp;August 2021.
The company exited the quarter with cash and equivalents worth $2.887 billion. Inventory totaled $13.048 billion.
Target&#8217;s long-term debt and other borrowings expanded to $14.334 billion, compared with $13.487 billion a year ago.
In a separate release, the company said that Christina Hennington, chief strategy and growth officer, will depart Target and move into a strategic <a href="https://www.benzinga.com/pressreleases/25/05/n45537767/target-corporation-announces-multi-year-enterprise-acceleration-office" target="_blank" rel="noreferrer noopener">advisor role through Sept. 7, 2025.</a> Jim Lee, chief financial officer, will take on leadership of Target&#8217;s enterprise strategy and partnerships.
Outlook: Target lowered its FY2025 adjusted EPS guidance from $8.80–$9.80 to $7.00–$9.00 versus the $8.48 estimate and saw a sales decline in the low single digits.
Target also revised its FY2025 GAAP EPS guidance from $8.80–$9.80 to $8.00–$10.00.
Price Action: TGT shares are trading lower by 2.58% to $95.59 at last check Wednesday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/short-ideas/25/05/45517463/top-2-risk-off-stocks-that-are-ticking-portfolio-bombs" target="_blank" rel="noreferrer noopener">Top 2 Risk Off Stocks That Are Ticking Portfolio Bombs</a></li>
</ul>
Photo: Shutterstock

General

Target Stock Slips As Q1 Earnings Miss Estimates, FY2025 Outlook Cut Amid Slowing Sales

SRPT

Sarepta Therapeutics shares are trading higher after the company provided dosing updates on its ENVISION study of ELEVIDYS.

Reshape Lifesciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RSLS#NASDAQ">RSLS</a>) reported quarterly earnings of $18.98 per share. This is a 114.02 percent increase over losses of $(135.37) per share from the same period last year. The company reported $1.11 million in sales this quarter. This is a 42.75 percent decrease over sales of $1.94 million the same period last year.

RSLS

Reshape Lifesciences Q1 EPS $18.98 Up From $(135.37) YoY, Sales $1.11M Down From $1.94M YoY

Digital Ally (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DGLY#NASDAQ">DGLY</a>) reported quarterly earnings of $1.41 per share. This is a 105.13 percent increase over losses of $(27.48) per share from the same period last year. The company reported $4.40 million in sales this quarter. This is a 20.42 percent decrease over sales of $5.53 million the same period last year.

DGLY

Digital Ally Q1 EPS $1.41 Up From $(27.48) YoY, Sales $4.4M Down From $5.53M YoY

Guggenheim analyst Steven Forbes reiterates Home Depot (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HD#NYSE">HD</a>) with a Buy and maintains $450 price target.

Guggenheim Reiterates Buy on Home Depot, Maintains $450 Price Target

Garrett Motion shares are trading lower after the company announced a secondary offering consisting of 17 million shares.

Jefferies analyst David Chiaverini initiates coverage on Valley Ntl (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VLY#NASDAQ">VLY</a>) with a Hold rating and announces Price Target of $10.

Jefferies Initiates Coverage On Valley Ntl with Hold Rating, Announces Price Target of $10

Dycom Industries shares are trading higher after the company reported better-than-expected Q1 financial results, issued Q2 sales guidance above estimates, and raised its FY26 sales guidance.

ECD Automotive Design (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ECDA#NASDAQ">ECDA</a>) reported quarterly losses of $(0.08) per share. This is a 11.11 percent increase over losses of $(0.09) per share from the same period last year. The company reported $6.42 million in sales this quarter. This is a 8.13 percent decrease over sales of $6.99 million the same period last year.

ECDA

ECD Automotive Design Q1 EPS $(0.08) Up From $(0.09) YoY, Sales $6.42M Down From $6.99M YoY

Guggenheim analyst John Difucci reiterates SentinelOne (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/S#NYSE">S</a>) with a Buy and maintains $28 price target.

Guggenheim Reiterates Buy on SentinelOne, Maintains $28 Price Target

Jefferies analyst David Chiaverini initiates coverage on Texas Capital Bancshares (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TCBI#NASDAQ">TCBI</a>) with a Hold rating and announces Price Target of $80.

Date	Put/Call	Strike Price	Exp Date	DTE	Trade Vol	Day Vol	Vol / OI	OI	Trade Type	Sentiment
09:56 AMMay 20, 2025	PUT	$75.00	Jun 27, 2025	36	6250	6250	41667	15	TRADE	BULLISH
09:54 AMMay 16, 2025	PUT	$75.00	Jul 18, 2025	57	5420	5027	1485	365	SWEEP	BULLISH

Comments

Cava Group

Unusual Options Activity for

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO